Literature DB >> 21326831

Lactococcus lactis as an adjuvant and delivery vehicle of antigens against pneumococcal respiratory infections.

Marcela Medina1, Elisa Vintiñi, Julio Villena, Raul Raya, Susana Alvarez.   

Abstract

Most studies of Lactococcus lactis as delivery vehicles of pneumococcal antigens are focused on the effectiveness of mucosal recombinant vaccines against Streptococcus pneumoniae in animal models. At present, there are three types of pneumococcal vaccines: capsular polysaccharide pneumococcal vaccines (PPV), protein-polysaccharide conjugate pneumococcal vaccines (PCV) and protein-based pneumococcal vaccines (PBPV). Only PPV and PCV have been licensed. These vaccines, however, do not represent a definitive solution. Novel, safe and inexpensive vaccines are necessary, especially in developing countries. Probiotic microorganisms such as lactic acid bacteria (LAB) are an interesting alternative for their use as vehicles in pneumococcal vaccines due to their GRAS (Generally Recognized As Safe) status. Thus, the adjuvanticity of Lactococcus lactis by itself represents added value over the use of other bacteria, a question dealt with in this review. In addition, the expression of different pneumococcal antigens as well as the use of oral and nasal mucosal routes of administration of lactococcal vaccines is considered. The advantages of nasal live vaccines are evident; nonetheless, oral vaccines can be a good alternative when the adequate dose is used. Another point addressed here is the use of live versus inactivated vaccines. In this sense, few researchers have focused on inactivated strains to be used as vaccines against pneumoccoccus. The immunogenicity of live vaccines is better than the one afforded by inactivated ones; however, the probiotic-inactivated vaccine combination has improved this matter considerably. The progress made so far in the protective immune response induced by recombinant vaccines, the successful trials in animal models and the safety considerations of their application in humans suggest that the use of recombinant vaccines represents a good short-term option in the control of pneumococcal diseases.
© 2010 Landes Bioscience

Entities:  

Keywords:  Lactococcus lactis; Streptococcus pneumoniae; recombinant vaccine

Mesh:

Substances:

Year:  2010        PMID: 21326831      PMCID: PMC3037581          DOI: 10.4161/bbug.1.5.12086

Source DB:  PubMed          Journal:  Bioeng Bugs        ISSN: 1949-1018


  80 in total

Review 1.  Microbes versus microbes: immune signals generated by probiotic lactobacilli and their role in protection against microbial pathogens.

Authors:  Martin L Cross
Journal:  FEMS Immunol Med Microbiol       Date:  2002-12-13

2.  Intracellular neutralization of virus by immunoglobulin A antibodies.

Authors:  M B Mazanec; C S Kaetzel; M E Lamm; D Fletcher; J G Nedrud
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-01       Impact factor: 11.205

3.  Immunomodulatory activity of Lactobacillus rhamnosus strains isolated from goat milk: impact on intestinal and respiratory infections.

Authors:  Susana Salva; Julio Villena; Susana Alvarez
Journal:  Int J Food Microbiol       Date:  2010-03-18       Impact factor: 5.277

4.  Effect of Lactobacillus casei and yogurt administration on prevention of Pseudomonas aeruginosa infection in young mice.

Authors:  S Alvarez; C Herrero; E Bru; G Perdigon
Journal:  J Food Prot       Date:  2001-11       Impact factor: 2.077

5.  Lactobacillus casei administration reduces lung injuries in a Streptococcus pneumoniae infection in mice.

Authors:  Silvia Racedo; Julio Villena; Marcela Medina; Graciela Agüero; Virginia Rodríguez; Susana Alvarez
Journal:  Microbes Infect       Date:  2006-07-07       Impact factor: 2.700

6.  Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic.

Authors:  V Enouf; P Langella; J Commissaire; J Cohen; G Corthier
Journal:  Appl Environ Microbiol       Date:  2001-04       Impact factor: 4.792

7.  Development of lactococcal GEM-based pneumococcal vaccines.

Authors:  Sandrine A L Audouy; Saskia van Selm; Maarten L van Roosmalen; Eduard Post; Rolf Kanninga; Jolanda Neef; Silvia Estevão; Edward E S Nieuwenhuis; Peter V Adrian; Kees Leenhouts; Peter W M Hermans
Journal:  Vaccine       Date:  2006-09-18       Impact factor: 3.641

8.  Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.

Authors:  Praveen Mannam; Kevin F Jones; Bruce L Geller
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

9.  Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production.

Authors:  Luis G Bermúdez-Humarán; Philippe Langella; Naima G Cortes-Perez; Alexandra Gruss; Reyes S Tamez-Guerra; Sergio C Oliveira; Odila Saucedo-Cardenas; Roberto Montes de Oca-Luna; Yves Le Loir
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

10.  Heterologous expression of the pneumococcal serotype 14 polysaccharide in Lactococcus lactis requires lactococcal epsABC regulatory genes.

Authors:  Masja N Nierop Groot; Jeroen Godefrooij; Michiel Kleerebezem
Journal:  Appl Environ Microbiol       Date:  2007-12-14       Impact factor: 4.792

View more
  12 in total

Review 1.  Early Lactococcus lactis endocarditis after mitral valve repair: a case report and literature review.

Authors:  C Rostagno; P Pecile; P L Stefàno
Journal:  Infection       Date:  2012-12-06       Impact factor: 3.553

Review 2.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

3.  Gut adhesive Bacillus subtilis spores as a platform for mucosal delivery of antigens.

Authors:  Milene Tavares Batista; Renata D Souza; Juliano D Paccez; Wilson B Luiz; Ewerton L Ferreira; Rafael C M Cavalcante; Rita C C Ferreira; Luís C S Ferreira
Journal:  Infect Immun       Date:  2014-01-13       Impact factor: 3.441

4.  Host immunity in the protective response to nasal immunization with a pneumococcal antigen associated to live and heat-killed Lactobacillus casei.

Authors:  Elisa O Vintiñi; Marcela S Medina
Journal:  BMC Immunol       Date:  2011-08-11       Impact factor: 3.615

5.  The development of lower respiratory tract microbiome in mice.

Authors:  Nisha Singh; Asheema Vats; Aditi Sharma; Amit Arora; Ashwani Kumar
Journal:  Microbiome       Date:  2017-06-21       Impact factor: 14.650

6.  Recombinant Lactococcus lactis Expressing Haemagglutinin from a Polish Avian H5N1 Isolate and Its Immunological Effect in Preliminary Animal Trials.

Authors:  Agnieszka K Szczepankowska; Katarzyna Szatraj; Przemysław Sałański; Agnieszka Rózga; Roman K Górecki; Jacek K Bardowski
Journal:  Biomed Res Int       Date:  2017-02-22       Impact factor: 3.411

7.  Infective Endocarditis in a Young Adult due to Lactococcus lactis: A Case Report and Review of the Literature.

Authors:  G Georgountzos; C Michopoulos; C Grivokostopoulos; M Kolosaka; N Vlassopoulou; A Lekkou
Journal:  Case Rep Med       Date:  2018-03-04

8.  Phase 1 Safety and Immunogenicity Trial of Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine.

Authors:  Sedigheh Taghinezhad-S; Amir Hossein Mohseni; Hossein Keyvani; Mohammad Reza Razavi
Journal:  Mol Ther Methods Clin Dev       Date:  2019-08-29       Impact factor: 6.698

Review 9.  Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines.

Authors:  Julio Villena; Chang Li; Maria Guadalupe Vizoso-Pinto; Jacinto Sacur; Linzhu Ren; Haruki Kitazawa
Journal:  Microorganisms       Date:  2021-03-26

10.  Development of Streptococcus pneumoniae Vaccines Using Live Vectors.

Authors:  Shifeng Wang; Roy Curtiss
Journal:  Vaccines (Basel)       Date:  2014-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.